Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022;47(3):264-272.
doi: 10.1016/j.meddos.2022.04.004. Epub 2022 May 23.

Comparing the robustness of different skin flash approaches using wide tangents, manual flash VMAT, and simulated organ motion robust optimization VMAT in breast and nodal radiotherapy

Affiliations

Comparing the robustness of different skin flash approaches using wide tangents, manual flash VMAT, and simulated organ motion robust optimization VMAT in breast and nodal radiotherapy

Ian Gleeson. Med Dosim. 2022.

Abstract

Compare the robustness of wide tangents (WT) and volumetric modulated arc therapy (VMAT) using different skin flash approaches in breast and nodal radiotherapy. Ten patients treated with WT using 2-cm flash were replanned with VMAT using no flash (NF), manual 2-cm flash (MF), and robust optimization (RO). Plan robustness was assessed for target coverage and organs at risk (OAR) by recalculating on 5 deformed CT scans (SOM1-5), daily cone beam (CBCT), and by shifting the isocenter 5 mm. VMAT NF gave poor coverage of CTVp with its smallest change of -3.2% for V38Gy on CBCT. VMAT RO plans showed the least variations in target coverage loss compared to WT and VMAT MF which dropped as anatomical swelling increased. CTVp D0.5cc decreased on CBCT and increased most for VMAT MF plans (case max increase +3.3 Gy), whereas VMAT RO plans were relatively stable (case max increase +1.2 Gy). OAR dose changed little with anatomical changes (isocenter shifts more important with medial, posterior, and inferior increasing dose). Nodal coverage was superior for VMAT which led to the WT being less robust for coverage toward both geometric and anatomical uncertainties. All techniques except NF plans gave high levels of coverage under minor uncertainties. VMAT RO was highly robust for target coverage for anatomical changes. Manually editing control points on VMAT plans was time-consuming and less predictable. CBCT anatomical changes were modest resulting in small delivered dose changes. OAR dose changes were small with no significant differences between techniques.

Keywords: Breast cancer; Dosimetric comparison; Robust optimization; VMAT.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest The authors declare no conflicts of interest.

Figures

Fig. 1
Fig. 1
Example beams eye view of the 4 techniques (WT, VMAT NF, VMAT MF, and VMAT RO). PTVp is red (WT field based), body is green and PTVn_LN orange. (Color version of figure is available online.)
Fig. 2
Fig. 2
Mean CTV dose differences for the 4 techniques (WT, VMAT NF, VMAT MF, and VMAT RO) for isocenter shifts and anatomical changes. (Color version of figure is available online.)
Fig. 3
Fig. 3
Mean OAR dose differences for the 4 techniques (WT, VMAT NF, VMAT MF, and VMAT RO) for isocenter shifts and anatomical changes. (Color version of figure is available online.)

References

    1. World Health Organisation. 2021. [Accessed November 2021]. Available at: https://www.who.int/news-room/fact-sheets/detail/cancer.
    1. Cancer Research UK. [Accessed November 2021]. Available at: https://www.cancerresearchuk.org/health-professional/cancer-statistics/s....
    1. The Royal College of Radiologists Postoperative radiotherapy for breast cancer: UK consensus statements. [Accessed November 2021];Clinical Oncol. 2016 November; Available at: https://www.rcr.ac.uk/system/files/publication/field_publication_files/b....
    1. Locke I, Drinkwater K. Implementation of Royal College of Radiologists Consensus Statements and National Institute for Health and Care Excellence Guidance: breast radiotherapy practice in the UK. Clin Oncol. 2021;33(7):419–26. doi: 10.1016/j.clon.2021.01.012. - DOI - PubMed
    1. Bjerregaard Stick L, Laugaard Lorenzen E, Svitzer Yates E, et al. Selection criteria for early breast cancer patients in the DBCG proton trial—The randomised phase III trial strategy. Clin Transl Radiat Oncol. 2021;27:126–31. doi: 10.1016/j.ctro.2021.01.012. - DOI - PMC - PubMed

LinkOut - more resources